Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 900435 in acute exacerbation of schizophrenia
NCT00988728Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Feb 2011
- Primary completion
- Jul 2012
01
Overview
A Phase 2 trial of org 25935 in schizophrenia, sponsored by Merck & Co.. Planned start Feb 2011; status: withdrawn.
02
Drugs
org 25935
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00988728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00988728.